Zenas Biopharma Inc’s filing revealed that its Director Nunn Jason Raleigh acquired Company’s shares for reported $1.2 million on Oct 09 ’25. In the deal valued at $19.00 per share,63,158 shares were bought. As a result of this transaction, Nunn Jason Raleigh now holds 1,173,395 shares worth roughly $42.1 million.
Then, SR ONE CAPITAL MANAGEMENT, LLC bought 126,315 shares, generating $2,399,985 in total proceeds. Upon buying the shares at $19.00, the 10% Owner now owns 1,917,895 shares.
Before that, ENRIGHT PATRICK G bought 105,265 shares. Zenas Biopharma Inc shares valued at $2,000,035 were divested by the Director at a price of $19.00 per share. As a result of the transaction, ENRIGHT PATRICK G now holds 1,832,669 shares, worth roughly $65.76 million.
Wedbush initiated its Zenas Biopharma Inc [ZBIO] rating to an Outperform in a research note published on March 20, 2025; the price target was $35. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in early February with a ‘”an Outperform”‘ rating. H.C. Wainwright began covering ZBIO with “Buy” recommendation on December 16, 2024. Rodman & Renshaw started covering the stock on November 05, 2024. It rated ZBIO as “a Buy”.
Price Performance Review of ZBIO
On Monday, Zenas Biopharma Inc [NASDAQ:ZBIO] saw its stock jump 2.51% to $35.88. Over the last five days, the stock has gained 10.50%. Zenas Biopharma Inc shares have risen nearly 87.85% since the year began. Nevertheless, the stocks have risen 338.10% over the past one year. While a 52-week high of $36.63 was reached on 11/17/25, a 52-week low of $5.83 was recorded on 01/28/25.
Levels Of Support And Resistance For ZBIO Stock
The 24-hour chart illustrates a support level at 34.15, which if violated will result in even more drops to 32.42. On the upside, there is a resistance level at 37.26. A further resistance level may holdings at 38.64.
How much short interest is there in Zenas Biopharma Inc?
A steep rise in short interest was recorded in Zenas Biopharma Inc stocks on 2025-10-31, dropping by -0.85 million shares to a total of 4.77 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 5.62 million shares. There was a decline of -17.83%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on October 08, 2024 when Morgan Stanley began covering the stock and recommended ‘”an Overweight”‘ rating along with a $40 price target.
